Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 799 across all filing types
Latest filing 2020-08-17 Regulatory Filings
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming announces the publication of data from a compassionate use programme of RUCONEST® in COVID-19 patients in a peer-reviewed journal
Regulatory Filings Classification · 95% confidence The document is a press release from Pharming Group N.V. announcing the publication of data from a compassionate use programme of RUCONEST® in COVID-19 patients in a peer-reviewed journal. It details clinical outcomes and compares them to a control group. This type of announcement, which communicates significant operational or clinical updates outside of routine financial reporting (like 10-K or IR), often falls under general regulatory announcements or investor relations material. Since it is not a formal financial report (10-K, IR, ER, MRQ), nor a specific legal filing (DIRS, DVA), nor a presentation (IP), nor a management discussion (MDA), it best fits the general category for regulatory/company news releases that don't fit elsewhere, which is Regulatory Filings (RNS). The document length is moderate (5973 chars), and it is a direct announcement of an event/publication, not just an announcement *about* a report (which would be RPA).
2020-08-17 English
Pharming announces enrolment of first patient in multinational clinical trial for the treatment of COVID-19 with RUCONEST®
Regulatory Filings Classification · 95% confidence The document is an announcement from Pharming Group N.V. dated August 10, 2020, detailing the enrollment of the first patient in a clinical trial for RUCONEST® to treat COVID-19. It provides highlights, background on the drug, commentary from executives, and forward-looking statements. This content structure—announcing a significant operational/clinical development event, often including key data points or trial updates—is characteristic of a press release or a general corporate update. Since it is not a formal regulatory filing like a 10-K, a quarterly report (IR), a specific financial release (ER), or a management discussion (MDA), and it is not merely announcing the publication of another report (RPA), the most appropriate classification is a general Regulatory Filing (RNS), which serves as a broad category for significant corporate news releases that don't fit narrower definitions. The document length (10,497 chars) is substantial, indicating it is the primary content, not just a brief announcement of a report.
2020-08-10 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half of 2020 (H1 2020), containing detailed financial statements (Income Statement, Balance Sheet), financial highlights, operational updates, and a statement from the Board of Management. It provides substantive financial data and analysis rather than just an announcement of a report. Therefore, it is classified as an Interim/Quarterly Report. H1 2020
2020-07-30 English
Pharming Group reports financial results for the first half of 2020
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the six-month period ended June 30, 2020, titled 'Pharming Group reports financial results for the first half of 2020'. It includes detailed financial highlights, operational updates, and the full 'Condensed Consolidated Interim Financial Statements (unaudited)' including the statement of profit or loss, financial position, and cash flows. Since it contains substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2020
2020-07-30 English
Annual General Meeting of Shareholders
AGM Information Classification · 99% confidence The document explicitly states in the title and first paragraph that it is reporting on the 'Annual General Meeting of Shareholders (AGM)'. It details the outcomes of the meeting (proposals withdrawn/approved) and mentions that recordings and presentation slides from the AGM are available. This directly aligns with the definition of 'AGM Information' (Code: AGM-R). Although it mentions future EGM plans, the primary subject is the results of the meeting just held.
2020-05-21 English
Pharming Group announces the nomination of Barbara Yanni and Mark Pykett to the Board of Supervisory Directors
Board/Management Information Classification · 100% confidence The document explicitly announces the 'nomination of Barbara Yanni and Mark Pykett to its Board of Supervisory Directors' and mentions that an Extraordinary General Meeting of Shareholders is expected later for their official appointment. This content directly relates to changes in the company's board of directors and senior management. This aligns perfectly with the definition for Board/Management Information (MANG). The document is a press release announcing management changes, not a formal regulatory filing like a 10-K or a general regulatory announcement (RNS).
2020-05-20 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.